Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Alexander M. Menzies, M. T. Ashworth, S. Swann, R. F. Kefford, K. Flaherty, J. Weber, J. R. Infante, K. B. Kim, R. Gonzalez, O. Hamid, L. Schuchter, J. Cebon, J. A. Sosman, S. Little, P. Sun, G. Aktan, D. Ouellet, F. Jin, G. V. Long, A. Daud

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

Combined dabrafenib and trametinib (CombiDT) is an approved therapy for advanced BRAFV600E/K-mutant melanoma patients. This study shows that pyrexia is frequent and recurrent with CombiDT, but is not associated with baseline characteristics or drug efficacy. The etiology is unclear but may involve drug exposure. This requires further research, as do strategies to prevent recurrent pyrexia.

Original languageEnglish (US)
Article numbermdu529
Pages (from-to)415-421
Number of pages7
JournalAnnals of Oncology
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2015

Keywords

  • BRAF
  • Dabrafenib
  • Fever
  • Melanoma
  • Pyrexia
  • Trametinib

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Characteristics of pyrexia in BRAF<sup>V600E/K</sup> metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial'. Together they form a unique fingerprint.

Cite this